Press Detail

Biotest AG: Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services

News: Biotest AG / Key word(s): Miscellaneous

11.10.2017 / 07:00
The issuer is solely responsible for the content of this announcement.


Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services

- Biotest supports home treatment with a team of specialised nurses

- New approach aims to tailor haemophilia therapy to individual patient needs

- Biotest starts with the important haemophilia market Germany


Dreieich, 11 October 2017. Medically controlled home treatment allows patients with haemophilia to live an almost normal life and to minimise the risk of spontaneous bleeding. A prerequisite for a long-term safe treatment is a consistent and correct application of the preparations at home. With the new haemoPRO service, the support by a nurse, Biotest aims to provide patients, their relatives and caregivers with the necessary safety in the use of their haemophilia therapy. In this way, Biotest ensures that all patients are optimally treated according to their individual therapeutic scheme. The new service gives Biotest the opportunity to improve patient quality of life in its most important and largest haemophilia market in Germany.

The Biotest program haemoPRO supports where despite detailed briefings by physicians uncertainties in the correct application of the coagulation factor remain. In the haemophilia centres, the patients and their relatives are prepared for the home treatment and are extensively trained to work sterile, to properly dissolve the powder and apply intravenous injection. However, some patients and their relatives may still find it difficult to implement what has been learned in the centre in the private environment. Parents have uncertainties to find a suitable vein for their injection in their child. It is also possible that older patients are not able to inject themselves due to additional diseases. Furthermore, there are also physical limitations, such as an arm fracture, which temporarily makes a home treatment impossible.

In such and similar cases, haemoPRO's service is open to all patients treated with Biotest coagulation factors. If the patient agrees to the attendance of the haemoPRO service offered by the physician, a haemoPRO nurse will contact the patient and arrange visits. haemoPRO keeps the physician up-to-date on the training results after each contact. Thus, the patient's quality of life can be improved in close consultation with the treating physician.

About Haemophilia
As a lifelong inherited bleeding disorder, haemophilia affects about 1 in 10,000 people worldwide. Haemophilia is one of a number of such disorders that prevent blood from clotting properly. People with haemophilia experience prolonged internal bleeding that can result from a seemingly minor injury. Bleeding into joints and muscles causes severe pain and disability while bleeding into major organs, such as the brain, can cause death. Treating the bleeding episodes involves the prompt and proper use of clotting factor concentrates. Haemophilia A is caused by a deficiency of clotting factor VIII. Therefore, intravenously administered therapeutic factor VIII is often recognised as a foreign protein (antigen) by the patient's immune system. As a consequence up to 30% of patients with severe haemophilia develop antibodies against the therapeutic factor VIII. These antibodies are called inhibitors because they reduce or eliminate the therapeutic effect of factor VIII. Most inhibitors develop during early childhood and compromise the ability to effectively prevent or manage haemorrhages, resulting in a greater rate of disability, morbidity, complications and costs of therapy. The formation of inhibitors is the most serious complication of today's haemophilia treatment. Avoiding the risk of inhibitor development would be the most effective prerequisite for a continuous therapy enabling haemophilia patients to live an almost normal life without irreversible joint damage. For more information on haemophilia and FVIII, please visit the World Federation of Haemophilia website at

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406

PR contact
Dirk Neumüller
phone: +49-6103-801-269

Biotest AG, Landsteinerstr. 5, 63303 Dreieich,

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart


This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

11.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this